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Abstract: International asthma guidelines have recently focused on the concept of «control», which is the main outcome 
to reach and maintain in the long term management. Asthma control is associated with several positive consequences, 
both in terms of quality of life and pathophysiological findings. Combination therapy with inhaled corticosteroids (ICS) 
and long-acting-beta2-agonists (LABA) is recommended in a large part of asthmatic subjects (those who are not con-
trolled with low-dose ICS alone). 
Recently, a new beclomethasone/formoterol combination in an extrafine HFA formulation has been developed. This new 
technology allows to obtain a very high fine particle fraction which reaches lower airways, while the dose which remain 
in the upper airways and possibly responsible for systemic side effects is very low. Therefore, this combination allows a 
different dose ratio between BDP and the other ICS (budesonide, fluticasone), in favour of a lower dose of BDP. Recent 
studies have demonstrated the equivalence of this new combination with the other ICS/LABA combination, as regards all 
asthma outcomes. Then, this new BDP/formoterol combination may increase the possibility to manage adequately patients 
with moderate-to-severe asthma. 
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INTRODUCTION 
  Despite the great work performed in the last years in the 
dissemination and implementation of asthma guidelines, the 
control of asthma in the world and in Europe is still poor. 
Many surveys have been conducted on this point, showing 
that just a minority of asthmatics, particularly between sub-
jects with the greater level of severity, reach a good control 
of asthma [1]. There are several reasons for this inadequate 
management of asthma, including the underdiagnosis of the 
disease, the lack of appropriate pharmacologic strategies, and 
the low use of non pharmacologic strategies for the man-
agement of the disease (education, prevention, and adequate 
follow-up). 
  More recent guidelines have considered this problem, 
and they have simplified the management of asthma in order 
to have a better adherence of doctors and patients to the op-
timal strategy [2]. 
THE VALUE OF THE “CONTROL” OF ASTHMA 
  The aim of the management of asthma is now to reach 
and maintain the control of the disease. Considering that 
more ambitious aims (like the “cure” of asthma or the 
change in the natural history of the disease) are not realistic, 
the main outcome is to reach an almost complete remission 
of the disease, evaluated as the almost complete absence of 
daytime and nocturnal symptoms, rescue medication use and 
exacerbations, as well as a normal lung function and the ab-
sence of limitation in the daily life. This aim can be obtained  
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in a majority of asthmatic patients with an appropriate treat-
ment strategy, as demonstrated by the GOAL study [3]. 
  The control of asthma is defined according to the criteria 
reported in Fig. (1). With an integrated evaluation of symp-
toms, use of rescue medication, level of pulmonary function, 
and rate of exacerbations, the control of the disease can be 
evaluated in a fairly easy way. The assessment of the control 
is necessary for the decision about the asthma management: 
the lack of control requires immediately a change in the level 
of pharmacologic treatment and a revision of the manage-
ment plan, while a good control lead to consider the persis-
tence or the step-down in the level of asthma treatment. This 
method of the evaluation of the control is simple and easily 
performed by the patient and the doctor, and this may im-
prove the global management of the disease. 
  Reaching the control has positive consequences on the 
quality of life of the asthmatic patients [4], and reflects also 
in a progressive improvement of the indirect markers of air-
way inflammation [5]. 
STRATEGIES TO OBTAIN AND MAINTAIN THE 
CONTROL 
  Regular treatment with inhaled corticosteroids (ICS) is 
the cornerstone of asthma management. Some patients may 
reach the control with a monotherapy with low-dose ICS, but 
in a large part of asthmatic subjects this is not possible. In 
these cases, the best option is to use a combination with ICS 
and long-acting-beta2-agonists (LABA). Combination ther-
apy has been demonstrated able to obtain the control of 
asthma better than ICS alone [3, 6]. This fact has been re-
lated to the complementary effect of ICS and LABA on the 
different components of the disease (inflammation   
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synergistic effect [7]. For these reasons, combination therapy 
is recommended as a first line therapy for moderate-to-
severe asthmatic patients [1,8,9]. 
  Two ICS-LABA combinations have been studied in the 
last 10 years: salmeterol/fluticasone and formoterol/budeso-
nide. Few comparative studies have been reported, but a re-
cent metanalysis suggests a substantial equivalence of these 
two combinations [10]. 
A NEW FIXED ICS-LABA COMBINATION 
  Recently a new fixed ICS-LABA combination has been 
developed and it is currently on the market in many Euro-
pean countries. This combination includes beclomethasone 
propionate (100 mcg per each inhalation) and formoterol (6 
mcg per each inhalation). The main feature of this combina-
tion lays in the innovative formulation characterised by an 
extrafine particle size of drug particles. In fact, both BDP 
and formoterol display a mass median aerodynamic diameter 
(MMAD) in the range of 1.4-1.5 m. Consequently, the 
amount of drug delivered to the lung, and responsible for the 
therapeutic effect, is increased whereas the dose of the drug 
remaining in the upper airways (and potentially responsible 
for systemic side effects) is reduced. 
  These data lead to an equivalence between BDP in the 
extrafine HFA formulation and BDP in the traditional CFC 
formulation of 1:2.5 (Fig. 2) [11]. This means that a dose of 
100 mcg of BDP in extrafine HFA formulation is equivalent, 
in terms of efficacy, to 250 mcg of BDP in traditional CFC 
formulation, with a significant lower risk of systemic side 
effects. 
  Some studies have been performed in order to demon-
strate the efficacy of this new BDP/Formoterol combination. 
A first study was done in order to compare the new combina-
tion with the combination with BDP at higher doses in the  
 
traditional CFC formulation plus inhaled formoterol, admin-
istered with two different inhalers; a third group of patients 
was treated with BDP alone in the traditional CFC formula-
tion [12]. The study shows that the new BDP/Formoterol 
combination was equivalent to the traditional extemporary 
combination with higher doses of BDP in terms of pulmo-
nary function and rate of severe exacerbations, but it was 
better than comparators as regards the percentage of days 
without asthma symptoms or of days with asthma control 
(Fig.  3). Notably, morning serum cortisol levels increased 
significantly versus baseline with BDP/formoterol, but re-
mained substantially unchanged with the other regimens, 
suggesting that the control of asthma could be maintained at 
least as well as with traditional higher doses of BDP with the 
potential for lower side effects. 
  Two similar studies have been performed in order to 
show the non inferiority of this new combination in compari-
son with the other ICS-LABA combinations already present 
in the market. The first study compared the new 
BDP/formoterol in the extrafine HFA formulation with 
budesonide/formoterol combination; the dose ratio of BDP: 
Budesonide was 1:2, which is different from the traditional 
equivalence reported in the equivalence table of ICS in sev-
eral international guidelines [2, 8-9]. In this study, more than 
200 moderate asthmatic subjects, uncontrolled under ICS at 
doses lower than 1000 mcg of BDP or equivalent, were en-
rolled in a classic double blind randomised parallel group 3 
month study [13]. The main outcome of the study was morn-
ing peak expiratory flow (PEF). In both groups, PEF signifi-
cantly increased just after few weeks and remained higher 
than baseline during all the study period, without any signifi-
cant difference between both groups (Fig. 4). The same effi-
cacy was observed in the two groups as regards day-time and 
nocturnal symptoms, and the rate of asthma exacerbations. 
The second study used the same study design, comparing the  
 
 
Fig. (1). Definition of the different levels of asthma control according to International GINA Guidelines [2]. 
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new BDP/formoterol combination in extrafine HFA formula-
tion with the fluticasone/salmeterol combination [14]. In this 
study, the dose ratio of BDP:fluticasone was 1:1.25, again 
different from the traditional equivalence reported in the 
equivalence table of ICS. The characteristics of the studied 
population was identical to the previous paper, as well as the 
main outcome (morning PEF). Also this study confirmed the 
equivalence between this new combination with the oldest 
fluticasone/salmeterol combination at different dose, in 
terms of pulmonary function, asthma symptoms and exacer-
 
Fig. (2). Dose-effect ratio, in terms of FEV1 increase, of the two different formulations of beclomethasone: the traditional CFC formulation, 
and the new extra-fine HFA formulation. To obtain the same effect on FEV1 of 250 mcg of BDP in the traditional formulation, only 100 mcg 
of BDP in the new extra-fine HFA formulation is required [11a, 11b]. 
 
Fig. (3). Level of asthma control in patients treated with the new budesonide/formoterol extra-fine HFA formulation, the traditional combina-
tion by two distinct inhalers, or high dose beclomethasone alone [12]. 
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bations. Furthermore, a significant better improvement in 
forced vital capacity (FVC) was observed with the new 
BDP/formoterol combination in comparison with flutica-
sone/salmeterol combination (Fig. 5). This observation sug-
gests that the efficacy on may be better with the new 
BDP/Formoterol in the extrafine HFA formulation, due to 
the fine particle size of this combination. 
 
Fig. (4). Increase from baseline in the Peak Expiratory Flow (PEF) in subjects treated with the new beclomethasone/formoterol combination 
in extra-fine HFA formulation, in comparison with the traditional budesonide/formoterol combination. In both groups, PEF progressively 
increased, without any significant difference between two groups [13]. 
 
Fig. (5). Increase from baseline in the Forced Vital Capacity (FVC) in subjects treated with the new beclomethasone/formoterol combination 
in extra-fine HFA formulation, in comparison with the traditional fluticasone/salmeterol combination. In both groups, FVC progressively 
increased, but this increase was significantly better with the new beclomethasone/formoterol combination [16]. 
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  Other studies are in progress with this new combination, 
both in asthma (including the efficacy of BDP/formoterol as 
“maintenance and reliever” strategy) and in COPD.  
CONCLUSIONS 
  The main objective of the management of asthma is the 
clinical and functional control; this may be easily evaluated 
by an integrated measurement of the frequency of symptoms 
and rescue medication, the absence of limitation in daily life, 
the rate of exacerbations, and the level of pulmonary func-
tion. The combination between an inhaled corticosteroid and 
a long-acting-beta2-agonist is the preferred option in a large 
majority of asthmatic patients. Different pharmacologic 
strategies can be used in order to reach and maintain the con-
trol, allowing to tailor the therapeutic plan to the characteris-
tics of the patients or the disease. The new beclometha-
sone/formoterol combination may increase the possibility to 
manage asthma, using low dose ICS with a great clinical ef-
ficacy and a low risk of systemic side effects. 
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